1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6EB224316C12A6BD7852571C0004E31CE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/optimizing-oncology-market-research-analytics?opendocument
18
19opendocument
2034.229.24.100
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services

Optimizing Oncology Market Research & Analytics

ID: PSM-217


Features:

8 Data Graphics

16 Metrics

4 Narratives

1 Best Practices


Pages: 40


Published: Pre-2014


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
Market research and analytics organizations play a vital role in providing oncology brand teams with the information they need to make better decisions, quicker. In today's complex, rapidly changing oncology marketplace, it is more important than ever that these organizations launch the right activities at the right time with the right level of resources to provide a brand with a competitive edge.


This 40-slide presentation will help pharmaceutical and biotech companies evaluate and improve the effectiveness of their oncology market research and analytics (MR&A) programs.


Industries Profiled:
Pharmaceutical; Biotech; Diagnostic; Chemical; Manufacturing; Consumer Products; Medical Device


Companies Profiled:
Novartis; Genmab; Human Genome Sciences; Eli Lilly and Company; Genentech; Janssen Cilag Pharmaceutical; Ortho Biotech; Daiichi Pharmaceutical Co.; Ltd.; Bayer; Serono

Study Snapshot

This research originated from an original client research for a member of Best Practices, LLC Business Excellence Board (link to site). The research was based on a survey of directors and managers of market research and analytic functions in 11 leading pharmaceutical and biotechnology companieDistribution of MR&A Resources at each Phase of Drug Developments.

Key topics include:

  • Allocation of MR&A Resources across Functions, including Market research, Market Analytics, Forecasting, Competitive Intelligence, and Strategic Business Planning.
  • Levels of Market Research Activities by Product Development Phase
  • Distribution of Market Research Headcount and Budget by Product Development Phase
  • Budget Allocation Trends by MR&A Function
  • Level of Outsourcing of Market Research Studies and Projects
  • Degree of Centralization of Individual MR&A Functions
  • Market Research FTE’s per Oncology Product
  • Effective Internal Stakeholder Communication Methods
  • Key Lessons Learned - Successes and Risks

Key Findings

A large majority of the benchmark class commissions market research within Phase I of product development.
  • On average, the benchmarked companies allocate 20% of their Market Research & Analytics headcount to pre-Phase III activities.
  • Outsourcing dominates market research strategy at the benchmarked companies.